Duloxetine for Chronic Depression: a Double-blind Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-08-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the treatment of major depression. The investigators are testing whether this medicine is also effective for adults with chronic depression (dysthymic disorder or dysthymia).

Chronic depression, lasting two or more years, often causes significant suffering and impairment. The investigators study involves a 6 to 10 week double-blind Initial Phase during which half of the participants will take the new medication and half will take a placebo (an inactive look-alike pill). After the Initial Phase, a 12-week Continuation Phase will begin, during which all subjects can be treated with an FDA-approved antidepressant medication.

Eligible subjects may also receive MRI scans, to help the investigators understand how antidepressants work in treating depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Duloxetine for the Treatment of Dysthymia

NCT00185575

Depressive Disorder

COMPLETED NA

Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome

NCT00375973

Fatigue Syndrome, Chronic

COMPLETED PHASE2/PHASE3

Duloxetine in the Treatment of Melancholic Depression

NCT00191685

Depressive Disorder, Major

COMPLETED PHASE3

Switching to Duloxetine in Patients With Depression

NCT00696774

Depressive Disorder, Major

COMPLETED PHASE4

A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

NCT01000805

Major Depressive Disorder

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 22-week study of the tolerability, dosing, and efficacy of duloxetine in chronically depressed outpatients. Participants can have Dysthymic Disorder (Dysthymia), or Depression, Not Otherwise Specified (Depression NOS).

The first 10 weeks (Acute Phase) are double blind, placebo-controlled, and the second 12 weeks (Continuation Phase) is open-label and all subjects will receive active medication.

Tests of cytokine functioning will be performed and analyzed for treatment and placebo effects.

In addition, a subset of patients will be enrolled into an Magnetic Resonance Imaging (MRI) sub-study, in which a variety of brain imaging techniques (including anatomical MRI, functional MRI (fMRI), MR Spectroscopy, and Diffusion Tensor Imaging) will be performed at baseline and week 10. Duloxetine responders will have a third MRI performed at week 22.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dysthymic Disorder Depressive Disorder NOS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

duloxetine (cymbalta)

Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine

Group Type EXPERIMENTAL

Duloxetine (Cymbalta)

Intervention Type DRUG

duloxetine medication up to dose of 120 mg/day

Placebo treatment

placebo treatment: treatment with placebo capsules that match active medication capsules

Group Type PLACEBO_COMPARATOR

Duloxetine (Cymbalta)

Intervention Type DRUG

duloxetine medication up to dose of 120 mg/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Duloxetine (Cymbalta)

duloxetine medication up to dose of 120 mg/day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

duloxetine Cymbalta

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 20 to 75 years (ages 20 to 60 for MRI sub-study)
* diagnosis of dysthymic disorder (chronic depression) or depression NOS
* minimum of 2 years duration of current episode of depression

Exclusion Criteria

* current major depression
* diagnoses including delirium, dementia, bipolar disorder, schizophrenia
* substance abuse or dependence in the past 6 months
* pregnant or nursing women
* serious risk of suicide

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No